1
Paul Michael Scola, Fiona McPhee, Nicholas A Meanwell, Piyasena Hewawasam, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Warren K Volles, November 7, 2006: US07132504 (55 worldwide citation)

Compounds are disclosed having the general formula: wherein R1, R2, R3, R4, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


2

3
Carol Bachand, Makonen Belema, Daniel H Deon, Andrew C Good, Jason Goodrich, Clint A James, Rico Lavoie, Omar D Lopez, Alain Martel, Nicholas A Meanwell, Van N Nguyen, Jeffrey Lee Romine, Edward H Ruediger, Lawrence B Snyder, Denis R St Laurent, Fukang Yang, David R Langley, Lawrence G Hamann: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, February 9, 2010: US07659270 (43 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


4
Tao Wang, Owen B Wallace, Zhongxing Zhang, Nicholas A Meanwell, John A Bender: Antiviral azaindole derivatives. Bristol Myers Squibb Company, Samuel J DuBoff, November 5, 2002: US06476034 (40 worldwide citation)

The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.


5
Carol Bachand, Makonen Belema, Daniel H Deon, Andrew C Good, Jason Goodrich, Clint A James, Rico Lavoie, Omar D Lopez, Alain Martel, Nicholas A Meanwell, Van N Nguyen, Jeffrey Lee Romine, Edward H Ruediger, Lawrence B Snyder, Denis R St Laurent, Fukang Yang, David R Langley, Gan Wang, Lawrence G Hamann: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, June 29, 2010: US07745636 (35 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


6
Ny Sin, Andrew Charles Good, Brian Lee Venables, Paul Michael Scola, Nicholas A Meanwell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, January 29, 2008: US07323447 (34 worldwide citation)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for i ...


7
Jeffrey L Romine, Scott W Martin, Piyasena Hewawasam, Nicholas A Meanwell, Valentin K Gribkoff, John E Starrett Jr: Diphenyl oxadiazolones as potassium channel modulators. Bristol Myers Squibb Company, Aldo A Algieri, February 9, 1999: US05869509 (34 worldwide citation)

Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: ##STR1## wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R.sup.a, R.sup.b and ...


8
Nicholas A Meanwell, John J Wright: Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors. Bristol Myers Company, Robert H Uloth, October 4, 1988: US04775674 (34 worldwide citation)

Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl ether derivatives of formula ##STR1## wherein R.sub.1 is hydrogen, lower alkly, benzyl; R.sub.2 is hydrogen, halogen, lower alkyl, lower alkoxy; Alk is alkylene; Y is hydroxy and alkanoic or aralkanoic esters thereof, oxo ketone, dialkyla ...


9
Carol Bachand, Makonen Belema, Daniel H Deon, Andrew C Good, Jason Goodrich, Clint A James, Rico Lavoie, Omar D Lopez, Alain Martel, Nicholas A Meanwell, Van N Nguyen, Jeffrey Lee Romine, Edward H Ruediger, Lawrence B Snyder, Denis R St Laurent, Fukang Yang, David R Langley, Gan Wang, Lawrence G Hamann: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, April 27, 2010: US07704992 (32 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


10
Tao Wang, Zhongxing Zhang, Nicholas A Meanwell, John F Kadow, Zhiwei Yin, Qiufen May Xue, Alicia Regueiro Ren, John D Matiskella, Yasutsugu Ueda: Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives. Bristol Myers Squibb Company, John F Levis, Jennifer C Chapman, Samuel J DuBoff, April 8, 2008: US07354924 (32 worldwide citation)

This invention provides Compounds I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in com ...